PARD (Poniard Pharmaceuticals) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 24, 2026)


What is Poniard Pharmaceuticals Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Poniard Pharmaceuticals's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

PARD vs OBMP, NSPX, ATRX: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Poniard Pharmaceuticals's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Poniard Pharmaceuticals Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Poniard Pharmaceuticals's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Poniard Pharmaceuticals's Margin of Safety % (DCF Earnings Based) falls into.


Poniard Pharmaceuticals Business Description

Address 300 Elliott Avenue West, Suite 530, Seattle, CA, USA, 98119
Poniard Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of cancer therapeutics. Its product candidate is picoplatin, a new generation platinum-based cancer therapy.